Pharma Industry

The top news stories in medicine today.

What physicians need to know about a massive program that affects prices of medicines.

Medicare has a laudable goal to bargain for lower prices, but there’s a chance patients could lose out on billions in savings.

Vaccines, autism are part of Senate questioning as Casey Means, M.D., says she supports physicians and patients making decisions rather than depending on surgeon general pronouncements.

Trump spotlights drug-price transparency and Most Favored Nation pricing —signaling changes to Obamacare subsidies and hospital insurer rules.

Express Scripts says it has the same goal as the Federal Trade Commission: ‘Lowering drug costs for Americans.’

President Trump signed federal spending plan with new rules for PBMs; a leading PBM trade group says Big Pharma is to blame for high drug prices.

Pharma, MedTech and diagnostics still operate in separate lanes even as precision medicine, value-based care and outcome-focused models demand integrated systems of care.

New white paper argues pharmacy benefit managers’ slim margins reflect bookkeeping and consolidation, not necessarily low profits, as oversight push intensifies.

An explainer of the new initiative to lower costs for patients while reining in pharmaceutical makers, PBMs and insurance companies.

What clinicians should keep in mind when recommending LAI medications and helping patients receive consistent treatment

More steps are needed, including insurance coverage that could help patients.

GLP-1 drugs Wegovy, Zepbound will have lower prices and be covered by Medicare.

Part three of our three-part webinar series airs Nov. 4 at 7 p.m. ET, unpacking how most favored nation pricing, import tariffs and direct-to-consumer channels could ripple through payer contracts, 340B and practice economics.

President Trump vows to slash prices for weight-loss drugs down to $150, sparking investor concerns and renewed debate over U.S. drug pricing policy.

Joint KFF/Washington Post survey finds broad bipartisan support for food regulation — and sharp divides on vaccines and trust in public health institutions.

Pfizer was at the White House late last month; AstraZeneca touts expansion in Virginia.

In part two of MJH Life Sciences’ three-part series, experts dissect President Trump’s most-favored nation executive order, warning that its use of tariffs and foreign price benchmarks could upend drug markets and test the limits of federal authority.

Ohio State researchers say the billionaire entrepreneur’s Cost Plus Drug Company exposes how insurance premiums and middlemen drive up the true cost of neurologic medications.

Savings for patients could reach 85%, and more pharmaceutical companies will have more deals to come, administration says.

Out-of-pocket costs for popular diabetes and weight-related medications nearly doubled in 2025, with nearly universal prior authorization requirements, according to new JAMA research.

Trump’s “most favored nation” drug pricing order could lower costs but raise new challenges for physicians, patients and pharma.

RFK says ‘pharmaceutical ads hooked this country on prescription drugs,’ so a crackdown is coming.

HHS Secretary Kennedy, Ag Secretary Rollins roll out action steps for national initiative on health.

Silencing one channel without building credible alternatives risks leaving patients less informed and physicians more burdened.